News | April 04, 2011

Paul Scherrer Institute, Elekta Collaborate in Proton Therapy Development

April 4, 2011 – The Paul Scherrer Institute (PSI) in Switzerland and Elekta are collaborating to further develop treatment planning and oncology information systems (OIS) for proton therapy. Proton therapy is a form of external beam radiation that uses protons instead of X-rays or electrons to treat certain types of cancer and other diseases.

PSI integrated Elekta's XiO treatment planning system and MOSAIQ OIS into its Centre for Proton Therapy to manage the flow of information and image data between treatment delivery, treatment planning, treatment simulation and the patient's electronic medical record.

The company recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for XiO to plan spot scanning. Spot scanning a proton therapy delivery method that involves constructing a highly conformal placement of dose to the tumor by using thousands of small individual beamlets instead of a single large beam.

"Through XiO, Elekta provides a combination of advanced tools for scanned proton beam therapy. Elekta also provides a clear road map to further develop intensity modulated, image guided and adaptive proton therapy," said Antony Lomax, Ph.D., professor and head of medical physics at the Center for Proton Therapy at PSI. "A deciding factor in entering into this relationship was Elekta's willingness to leverage the significant experience of our team to increase the capabilities of XiO proton planning."

MOSAIQ is designed to support different types of radiation systems and modalities, including proton and carbon ion therapy, intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and volumetric modulated arc therapy (VMAT).

The Centre for Proton Therapy at PSI pioneered scanning beam proton therapy, and treated its first patients with this approach in 1996. Subsequently, PSI upgraded this treatment modality to deliver intensity modulated proton therapy (IMPT), treating its first patient with this technique in 1999.

"Radiation therapy is evolving rapidly in many areas, thanks in large part to innovations in intensity modulation, image guidance and workflow enhancing information management systems over the last decade," said Stewart Pegrum, director particle therapy, Elekta. "Elekta has driven most of these improvements on the linear accelerator, as centers such as the Paul Scherrer Institute have advanced the discipline of proton therapy. Our collaboration with PSI focuses on combining technological advances in conventional radiation therapy and proton therapy to create the best possible therapeutic solution. We firmly believe that both Elekta and its customers can substantially benefit from this collaboration as PSI is one of the leading institutions in the field of proton therapy."

For more information: www.elekta.com

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Baptist Hospital's Miami Cancer Institute Treats First Patient With Proteus Plus Proton Therapy
News | Proton Therapy | December 19, 2017
December 19, 2017 — IBA (Ion Beam Applications SA) announced that Miami Cancer Institute treated its first patients,
Mevion Achieves CE Mark for S250i Proton Therapy System
News | Proton Therapy | November 21, 2017
November 21, 2017 — Mevion Medical Systems announced the Mevion S250i...
RayStation Selected for New Tennessee Proton Therapy Center
News | Treatment Planning | November 20, 2017
November 20, 2017 — Provision Healthcare has selected RayStation for external beam planning at the new Provision Care
Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Feature | Proton Therapy | November 06, 2017 | By Larisa Brass, MPH
Thirty-three. Twenty-nine. Sixty-four. These are the ages of the breast cancer patients who have walked through the...
PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy
News | Proton Therapy | November 01, 2017
Physicians from across the country gathered in Chicago last week to discuss the most recent advances in proton therapy...
Proton Therapy Lowers Treatment Side Effects in Pediatric Head and Neck Cancer Patients
News | Proton Therapy | November 01, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional...
Proton Therapy Shows Promising Clinical Benefits for Esophageal, Prostate and Breast Cancer
News | Proton Therapy | October 30, 2017
The National Association for Proton Therapy (NAPT) announced a number of clinical papers showing promising results were...
Overlay Init